PDQ-39: a review of the development, validation and ap quality of life questionnaire and its associated measures

Journal of Neurology 245, S10-S14 DOI: 10.1007/pl00007730

Citation Report

#	Article	IF	CITATIONS
2	What contributes to quality of life in patients with Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 308-312.	0.9	1,092
3	Health-Related Quality of Life in Parkinson's Disease after Pallidotomy and Deep Brain Stimulation. Brain and Cognition, 2000, 42, 399-416.	0.8	63
4	Quality of life issues in motor neurone disease: the development and validation of a coping strategies questionnaire, the MND Coping Scale. Journal of the Neurological Sciences, 2001, 191, 79-85.	0.3	35
5	Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30. Obstetrics and Gynecology, 2001, 98, 258-264.	1.2	165
6	Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson??s Disease. Pharmacoeconomics, 2001, 19, 1013-1038.	1.7	105
7	CT-Guided Unilateral Thalamotomy with Macroelectrode Mapping for the Treatment of Parkinson's Disease. Acta Neurochirurgica, 2001, 143, 1019-1030.	0.9	12
8	Insomnia and depressive symptoms in patients with Parkinson's disease. Archives of Gerontology and Geriatrics, 2001, 32, 23-33.	1.4	92
9	Quality of life in Parkinson's disease: Greek translation and validation of the Parkinson's disease questionnaire (PDQ-39). Quality of Life Research, 2001, 10, 159-163.	1.5	32
10	Development of an Endometriosis Quality-of-Life Instrument. Obstetrics and Gynecology, 2001, 98, 258-264.	1.2	112
11	Preference-based quality-of-life in patients with Parkinson's disease. Neurology, 2002, 59, 103-108.	1.5	81
12	Levodopa Pharmacokinetics and Motor Performance During Activities of Daily Living in Patients With Parkinson's Disease on Individual Drug Combinations. Clinical Neuropharmacology, 2002, 25, 89-96.	0.2	78
13	Factors of importance to the caregiver burden experienced by family caregivers of Parkinson's disease patients. Aging Clinical and Experimental Research, 2002, 14, 371-377.	1.4	91
14	Health-Related quality of life in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei. Movement Disorders, 2002, 17, 539-545.	2.2	82
15	Long-Term follow-up of globus pallidus chronic stimulation in advanced Parkinson's disease. Movement Disorders, 2002, 17, 803-807.	2.2	66
16	Translation and validation of the standard Chinese version of PDQ-39: A quality-of-life measure for patients with Parkinson's disease. Movement Disorders, 2002, 17, 1036-1040.	2.2	55
17	Quality of life outcomes following surgical treatment of Parkinson's disease. Movement Disorders, 2002, 17, 68-75.	2.2	32
18	The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. Journal of Neurology, 2002, 249, 842-846.	1.8	180
19	The importance of educational and psychological factors in Parkinson's disease quality of life. European Journal of Neurology, 2002, 9, 589-593.	1.7	65

#	Article	IF	CITATIONS
20	Health-Related Quality of Life and sleep disorders in Parkinson?s disease. Neurological Sciences, 2003, 24, 209-210.	0.9	80
21	Young- versus older-onset Parkinson's disease: Impact of disease and psychosocial consequences. Movement Disorders, 2003, 18, 1250-1256.	2.2	234
22	The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurologica Scandinavica, 2003, 107, 1-6.	1.0	225
23	Economic burden and quality of life impairment increase with severity of PD. Parkinsonism and Related Disorders, 2003, 9, 163-168.	1.1	131
24	The psychometric properties of the Parkinson's Impact Scale (PIMS) as a measure of quality of life in Parkinson's disease. Parkinsonism and Related Disorders, 2003, 9, 291-294.	1.1	26
25	A novel quality of life instrument for deep brain stimulation in movement disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1023-1030.	0.9	41
26	The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation. Human Reproduction, 2004, 19, 371-377.	0.4	115
27	Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 749-753.	0.9	119
28	Sense of coherence is a sensitive measure for changes in subjects with Parkinson's disease during 1 year. Scandinavian Journal of Caring Sciences, 2004, 18, 154-159.	1.0	33
29	Improvement in quality of life in patients with advanced Parkinson's disease following bilateral deep-brain stimulation in subthalamic nucleus. European Journal of Neurology, 2004, 11, 451-454.	1.7	96
30	Quality of life in Polish patients with long-lasting Parkinson's disease. Movement Disorders, 2004, 19, 667-672.	2.2	45
31	Validity and reliability of the PDQ-39 and the PDQ-8 in English-speaking Parkinson's disease patients in Singapore. Parkinsonism and Related Disorders, 2004, 10, 493-499.	1.1	57
32	Review Paper: Measuring outcomes for neurological disorders: a review of disease-specific health status instruments for three degenerative neurological conditions. Chronic Illness, 2005, 1, 131-142.	0.6	9
33	The Impact of Group Composition on Internet Support Groups: Homogeneous Versus Heterogeneous Parkinson's Groups Group Dynamics, 2005, 9, 239-250.	0.7	48
34	Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurologica Scandinavica, 2005, 111, 21-28.	1.0	68
35	Impact of the motor complications of Parkinson's disease on the quality of life. Movement Disorders, 2005, 20, 224-230.	2.2	463
36	Gabapentin can improve postural stability and quality of life in primary orthostatic tremor. Movement Disorders, 2005, 20, 865-870.	2.2	40
37	Patient-perceived involvement and satisfaction in Parkinson's disease: Effect on therapy decisions and quality of life. Movement Disorders, 2005, 20, 616-619.	2.2	100

#	Article	IF	CITATIONS
38	Evaluation of acupuncture in the treatment of Parkinson's disease: A double-blind pilot study. Movement Disorders, 2005, 20, 1185-1188.	2.2	93
39	Suboptimal medication adherence in Parkinson's disease. Movement Disorders, 2005, 20, 1502-1507.	2.2	179
40	Validity and reliability of the Chinese (Singapore) version of the Parkinson's Disease Questionnaire (PDQ-39). Quality of Life Research, 2005, 14, 273-279.	1.5	24
41	Pallidal stimulation in dystonia: effects on cognition, mood, and quality of life. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1713-1716.	0.9	124
42	Prevalence and Treatment of Depression in Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2005, 17, 310-323.	0.9	107
43	Cost of Illness and its Predictors for Parkinson??s Disease in Germany. Pharmacoeconomics, 2005, 23, 817-836.	1.7	125
44	Bilateral subthalamic nucleus stimulation improves health-related quality of life in Parkinsonian patients. Parkinsonism and Related Disorders, 2005, 11, 89-94.	1.1	54
45	Balance and fear of falling in Parkinson's disease. Parkinsonism and Related Disorders, 2005, 11, 427-433.	1.1	116
47	A Review of the Health-Related Quality of Life and Economic Impact of Parkinson??s Disease. Drugs and Aging, 2006, 23, 693-721.	1.3	163
48	Quality of life and depression in Parkinson's disease. Journal of the Neurological Sciences, 2006, 248, 151-157.	0.3	320
49	Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism and Related Disorders, 2006, 12, 35-41.	1.1	419
50	Developing the Construct of Social Support in Parkinson's Disease. Physical and Occupational Therapy in Geriatrics, 2006, 24, 45-60.	0.2	11
51	Monitoring Activity in Individuals with Parkinson Disease. Journal of Neurologic Physical Therapy, 2006, 30, 12-21.	0.7	30
52	Living with primary ciliary dyskinesia: a prospective qualitative study of knowledge sharing, symptom concealment, embarrassment, mistrust, and stigma. BMC Pulmonary Medicine, 2006, 6, 25.	0.8	20
53	Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurology, The, 2006, 5, 235-245.	4.9	2,202
54	Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease. Movement Disorders, 2006, 21, 746-753.	2.2	56
55	Blinded placebo crossover study of gabapentin in primary orthostatic tremor. Movement Disorders, 2006, 21, 900-905.	2.2	45
56	The Parkinson's Disease Questionnaire (PDQ-39): evidence for a method of imputing missing data. Age and Ageing, 2006, 35, 497-502.	0.7	36

#	Article	IF	CITATIONS
57	Measuring quality of life in PSP: The PSP-QoL. Neurology, 2006, 67, 39-44.	1.5	61
58	Online Support Groups for Parkinson's Patients. Social Work in Health Care, 2006, 42, 23-38.	0.8	47
59	Stigmatization, Physical Illness and Mental Health in Primary Ciliary Dyskinesia. Journal of Health Psychology, 2006, 11, 467-482.	1.3	23
60	Effectiveness of physiotherapy in Parkinson's disease: The feasibility of a randomised controlled trial. Parkinsonism and Related Disorders, 2007, 13, 115-121.	1.1	39
61	Testing the validity of the PDQ-39 in patients with MSA. Parkinsonism and Related Disorders, 2007, 13, 152-156.	1.1	5
62	An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease. Clinical Neurophysiology, 2007, 118, 2189-2194.	0.7	83
63	Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Movement Disorders, 2007, 22, 1239-1244.	2.2	153
64	Determinants of quality of life in Brazilian patients with Parkinson's disease. Movement Disorders, 2007, 22, 1408-1415.	2.2	80
65	Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced Parkinson's disease. Movement Disorders, 2007, 22, 1866-1870.	2.2	53
66	The suitability of patient-based measures in the field of Parkinson's disease: A systematic review. Movement Disorders, 2007, 22, 1390-1401.	2.2	46
67	Quality of life and related concepts in Parkinson's disease: A systematic review. Movement Disorders, 2007, 22, 1528-1537.	2.2	137
68	Measuring healthâ€related quality of life in MSA: The MSAâ€QoL. Movement Disorders, 2007, 22, 2332-2338.	2.2	49
69	Longâ€ŧerm effectiveness and quality of life improvement in entacaponeâ€ŧreated Parkinson's disease patients: the effects of an early therapeutic intervention. European Journal of Neurology, 2007, 14, 282-289.	1.7	17
70	Rasch analysis of the short form 8-item Parkinson's Disease Questionnaire (PDQ-8). Quality of Life Research, 2008, 17, 541-548.	1.5	32
71	Sertraline in the treatment of depressive disorders in patients with Parkinson's disease. Neurological Sciences, 2008, 29, 391-395.	0.9	21
72	Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Movement Disorders, 2008, 23, 1665-1672.	2.2	159
73	Factors affecting healthâ€related quality of life amongst Asian patients with Parkinson's disease. European Journal of Neurology, 2008, 15, 737-742.	1.7	45
74	Anxiety and depression: Main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 102-108.	1.1	96

#	Article	IF	CITATIONS
75	An Evaluation of a Cognitive-Behavioral Patient Education Program for Persons with Parkinson's Disease in Finland. Nordic Psychology, 2008, 60, 316-331.	0.4	7
76	Cost Effectiveness of Pharmacotherapies in Early Parkinson's Disease. CNS Drugs, 2008, 22, 841-860.	2.7	16
77	Neuropsychological Issues in Deep Brain Stimulation of Neurological and Psychiatric Disorders. , 2008, , 399-452.		1
78	Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD - Adjunct Study). Progress in Neurotherapeutics and Neuropsychopharmacology, 2008, 3, .	0.0	0
79	Depressive symptoms and perception of quality of life in Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2009, 67, 203-208.	0.3	33
80	Predictors of Health Status in Nondepressed and Nondemented Individuals with Parkinson's Disease. Archives of Clinical Neuropsychology, 2009, 24, 699-709.	0.3	7
81	Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Movement Disorders, 2009, 24, 25-31.	2.2	39
82	Comparative responsiveness of Parkinson's disease scales to change over time. Movement Disorders, 2009, 24, 813-818.	2.2	62
83	Fatigue in Japanese patients with Parkinson's disease: A study using Parkinson fatigue scale. Movement Disorders, 2009, 24, 1977-1983.	2.2	32
84	Neuroticism and extraversion in association with quality of life in patients with Parkinson's disease. Quality of Life Research, 2009, 18, 33-42.	1.5	41
85	SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Quality of Life Research, 2009, 18, 1219-37.	1.5	40
86	Telephone-Administered Cognitive Behavioral Therapy: A Case Study of Anxiety and Depression in Parkinson's Disease. Journal of Clinical Psychology in Medical Settings, 2009, 16, 243-253.	0.8	63
87	The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease. Acta Neurologica Scandinavica, 2009, 119, 397-403.	1.0	43
88	Cross-Cultural Validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS) in Four Latin American Countries. Value in Health, 2009, 12, 385-391.	0.1	10
89	Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2009, 301, 63.	3.8	1,253
90	The association of type D personality with quality of life in patients with Parkinson's disease. Aging and Mental Health, 2009, 13, 905-912.	1.5	23
91	High intensity eccentric resistance training decreases bradykinesia and improves quality of life in persons with Parkinson's disease: A preliminary study. Parkinsonism and Related Disorders, 2009, 15, 752-757.	1.1	178
92	Inappropriate crying and laughing in Parkinson disease and movement disorders. World Journal of Biological Psychiatry, 2009, 10, 234-240.	1.3	36

#	Article	IF	CITATIONS
93	Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies. Parkinsonism and Related Disorders, 2009, 15, S85-S92.	1.1	12
94	The Role of Mild Depression in Sleep Disturbance and Quality of Life in Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2010, 22, 384-389.	0.9	37
95	Quality of Life in Parkinson's Disease Patients Following Adjunctive Tolcapone Therapy: Results of an Open-Label, Multicenter, Community-Based Trial. CNS Spectrums, 2010, 15, 27-32.	0.7	5
96	Responsiveness of the EQ-5D and 8-item Parkinson's Disease Questionnaire (PDQ-8) in a 4-year follow-up study. Quality of Life Research, 2010, 19, 565-569.	1.5	24
97	Efficacy of community-based physiotherapy networks for patients with Parkinson's disease: a cluster-randomised trial. Lancet Neurology, The, 2010, 9, 46-54.	4.9	143
98	Selfâ€rated health status in spinocerebellar ataxia—Results from a European multicenter study. Movement Disorders, 2010, 25, 587-595.	2.2	74
99	The ParkinsonNet trial: Design and baseline characteristics. Movement Disorders, 2010, 25, 830-837.	2.2	12
100	Selfâ€management rehabilitation and healthâ€related quality of life in Parkinson's disease: A randomized controlled trial. Movement Disorders, 2010, 25, 194-204.	2.2	136
101	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBSâ€₽D). Movement Disorders, 2010, 25, 1530-1537.	2.2	20
102	Nonmotor symptoms are independently associated with impaired healthâ€related quality of life in Chinese patients with Parkinson's disease. Movement Disorders, 2010, 25, 2740-2746.	2.2	101
103	Correlação das escalas de avaliação utilizadas na doença de Parkinson com aplicabilidade na fisioterapia. Fisioterapia Em Movimento, 2010, 23, 121-127.	0.4	13
104	Effects of treadmill-walking training with additional body load on quality of life in subjects with Parkinson's disease. Brazilian Journal of Physical Therapy, 2010, 14, 344-350.	1.1	24
105	Parkinson's disease: Impact of clinical and cognitive aspects on quality of life. Dementia E Neuropsychologia, 2010, 4, 131-137.	0.3	9
106	Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability. ClinicoEconomics and Outcomes Research, 2010, 2, 127.	0.7	3
107	The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease. Neurologist, 2010, 16, 76-83.	0.4	28
108	Care requirements of a prevalent population of people with idiopathic Parkinson's disease. Age and Ageing, 2010, 39, 57-61.	0.7	19
109	Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease. New England Journal of Medicine, 2010, 362, 2077-2091.	13.9	1,187
110	Sexual and relationship dysfunction in people with Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 172-176.	1.1	49

#	Article	IF	CITATIONS
111	Do metronomes improve the quality of life in people with Parkinson's disease? A pragmatic, single-blind, randomized cross-over trial. Clinical Rehabilitation, 2010, 24, 523-532.	1.0	16
112	Measuring participation in individuals with Parkinson disease: relationships with disease severity, quality of life, and mobility. Disability and Rehabilitation, 2011, 33, 1440-1446.	0.9	79
113	Locus of control, depression, and quality of life in Parkinson's Disease. Journal of Health Psychology, 2011, 16, 980-987.	1.3	19
114	Trajectory Classes of Decline in Health-Related Quality of Life in Parkinson's Disease: A Pilot Study. Value in Health, 2011, 14, 329-338.	0.1	9
115	Five Times Sit-to-Stand Test Performance in Parkinson's Disease. Archives of Physical Medicine and Rehabilitation, 2011, 92, 1431-1436.	0.5	202
116	Anxiety and self-perceived health status in Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 249-254.	1.1	54
117	Which measures of physical function and motor impairment best predict quality of life in Parkinson's disease?. Parkinsonism and Related Disorders, 2011, 17, 693-697.	1.1	120
118	Measuring quality of life in multiple system atrophy. , 0, , 60-70.		0
119	Measuring quality of life in progressive supranuclear palsy. , 2011, , 52-59.		1
120	Fatigue in Patients with Parkinson's Disease: Impact on Quality of Life. Internal Medicine, 2011, 50, 1553-1558.	0.3	34
121	Pramipexole Reduces the Prevalence of Fatigue in Patients with Parkinson's Disease. Internal Medicine, 2011, 50, 2163-2168.	0.3	17
122	Behavioral and personality features in patients with lateralized Parkinson's disease. European Journal of Neurology, 2011, 18, 772-777.	1.7	11
123	Culture, gender and health care stigma: Practitioners' response to facial masking experienced by people with Parkinson's disease. Social Science and Medicine, 2011, 73, 95-102.	1.8	71
124	The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial. Trials, 2011, 12, 251.	0.7	8
125	Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Movement Disorders, 2011, 26, 331-334.	2.2	27
126	Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A doubleâ€blind, randomized, placeboâ€controlled study (RECOVER). Movement Disorders, 2011, 26, 90-99.	2.2	394
127	Preâ€operative evaluations for DBS in dystonia. Movement Disorders, 2011, 26, S17-22.	2.2	16
128	Quality of life in young―compared with lateâ€onset Parkinson's disease. Movement Disorders, 2011, 26, 2011-2018.	2.2	63

#	Article	IF	CITATIONS
129	Visual symptoms in Parkinson's disease and Parkinson's disease dementia. Movement Disorders, 2011, 26, 2387-2395.	2.2	164
130	Outcome Measures in Neurological Physical Therapy Practice. Journal of Neurologic Physical Therapy, 2011, 35, 57-64.	0.7	73
131	Factors Associated With Exercise Behavior in People With Parkinson Disease. Physical Therapy, 2011, 91, 1838-1848.	1.1	134
132	Using the WHOQOL-DIS to Measure Quality of Life in Persons with Physical Disabilities Caused by Neurodegenerative Disorders. Neurodegenerative Diseases, 2011, 8, 178-186.	0.8	21
133	The effects of deep brain stimulation on sleep in Parkinson's disease. Therapeutic Advances in Neurological Disorders, 2011, 4, 15-24.	1.5	47
134	Cognitive behavioural therapy for depression in advanced Parkinson's disease: a case illustration. The Cognitive Behaviour Therapist, 2012, 5, 60-69.	0.4	3
135	Randomized trial of deep brain stimulation for Parkinson disease. Neurology, 2012, 79, 55-65.	1.5	386
136	Beyond Mere Symptom Relief in Deep Brain Stimulation: An Ethical Obligation for Multifaceted Assessment of Outcome. AJOB Neuroscience, 2012, 3, 44-49.	0.6	27
137	Health-Related Quality of Life of Australians with Parkinson Disease: A Comparison with International Studies. Physiotherapy Canada Physiotherapie Canada, 2012, 64, 338-346.	0.3	8
138	Assessment of the Effects of Unilateral Electrode Dysfunction in Patients With Parkinson Disease Undergoing Bilateral Subthalamic Nucleus Deep Brain Stimulation. Operative Neurosurgery, 2012, 70, ons163-ons169.	0.4	0
139	Reliability and validity of PDQ-39: a quality-of-life measure for patients with PD in China. Quality of Life Research, 2012, 21, 1217-1221.	1.5	13
140	Markov blanket-based approach for learning multi-dimensional Bayesian network classifiers: An application to predict the European Quality of Life-5 Dimensions (EQ-5D) from the 39-item Parkinson's Disease Questionnaire (PDQ-39). Journal of Biomedical Informatics, 2012, 45, 1175-1184.	2.5	37
141	Caffeine for treatment of Parkinson disease. Neurology, 2012, 79, 651-658.	1.5	252
142	Dopamine transporter imaging is associated with longâ€ŧerm outcomes in Parkinson's disease. Movement Disorders, 2012, 27, 1392-1397.	2.2	115
143	Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson's disease: Results from a 1-year, open-label extension of the RECOVER study. Basal Ganglia, 2012, 2, 79-85.	0.3	20
144	Impact of changes in balance and walking capacity on the quality of life in patients with Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2012, 70, 119-124.	0.3	31
145	Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease. Neurological Sciences, 2012, 33, 847-853.	0.9	10
146	Oroâ€buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort. European Journal of Neurology, 2012, 19, 28-37.	1.7	76

#	Article	IF	CITATIONS
147	Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. European Journal of Neurology, 2012, 19, 105-113.	1.7	84
148	Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease. Quality of Life Research, 2013, 22, 1065-1072.	1.5	22

Advanced Parkinson's disease: Clinical characteristics and treatment (part 1). NeurologÃa (English) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50

150	Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview. Expert Review of Neurotherapeutics, 2013, 13, 1329-1342.	1.4	5
151	Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits. Lancet Neurology, The, 2013, 12, 1025-1034.	4.9	117
153	Impaired Sexual Function. , 2013, , 173-186.		1
154	Effectiveness of multidisciplinary care for Parkinson's disease: A randomized, controlled trial. Movement Disorders, 2013, 28, 605-611.	2.2	111
155	Self reported adherence to a home-based exercise programme among people with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 66-71.	1.1	32
156	Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2013, 36, 67-75.	0.7	47
157	Nonmotor Symptoms in Nursing Home Residents with Parkinson's Disease: Prevalence and Effect on Quality of Life. Journal of the American Geriatrics Society, 2013, 61, 1714-1721.	1.3	62
158	Preliminary results of ON/OFF detection using an integrated system for Parkinson's disease monitoring. , 2013, 2013, 941-4.		13
159	A twoâ€year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Movement Disorders, 2013, 28, 1230-1240.	2.2	235
160	Impact of Falls and Fear of Falling on Health-Related Quality of Life in Patients with Parkinson's Disease, 2013, 3, 409-413.	1.5	76
161	Exploring Outcome Measures for Exercise Intervention in People with Parkinson's Disease. Parkinson's Disease, 2013, 2013, 1-9.	0.6	42
162	Effects of Sleep Disorders on the Non-Motor Symptoms of Parkinson Disease. Journal of Clinical Sleep Medicine, 2013, 09, 1119-1129.	1.4	97
163	Activities of Daily Living, Depression, and Quality of Life in Parkinson's Disease. PLoS ONE, 2014, 9, e102294.	1.1	57
164	Comparison of the Psychological Symptoms and Disease-Specific Quality of Life between Early- and Typical-Onset Parkinson's Disease Patients. Parkinson's Disease, 2014, 2014, 1-7.	0.6	14
165	Antiatherosclerotic Effect of Korean Red Ginseng Extract Involves Regulator of G-Protein Signaling 5. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-11.	0.5	8

#	Article	IF	CITATIONS
166	Can Cognitive Remediation Improve Mobility in Patients with Parkinson's Disease? Findings from a 12 week Pilot Study. Journal of Parkinson's Disease, 2014, 4, 37-44.	1.5	35
167	Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial. Trials, 2014, 15, 465.	0.7	25
168	Cross-Cultural Validity, Reliability, and Psychometric Properties of the Persian Version of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire. Neurology Research International, 2014, 2014, 1-7.	0.5	5
169	Randomized, controlled trial of rasagiline as an addâ€on to dopamine agonists in Parkinson's disease. Movement Disorders, 2014, 29, 1028-1034.	2.2	44
170	Is Median Nerve Enlargement at the Wrist Associated With Tremor in Parkinson Disease?. Journal of Ultrasound in Medicine, 2014, 33, 2079-2083.	0.8	7
171	Selfâ€rated health mediates the association between functional status and healthâ€related quality of life in <scp>P</scp> arkinson's disease. Journal of Clinical Nursing, 2014, 23, 1970-1977.	1.4	5
172	Effect of the Ai-Chi Method on Functional Activity, Quality of Life, and Posture in Patients With Parkinson Disease. Topics in Geriatric Rehabilitation, 2014, 30, 282-289.	0.2	17
173	Validation of the Korean version of the 39-Item Parkinson's Disease Questionnaire (PDQ-39). Asian Nursing Research, 2014, 8, 67-74.	0.7	11
174	A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease. BMC Psychiatry, 2014, 14, 19.	1.1	63
175	Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD). Health and Quality of Life Outcomes, 2014, 12, 11.	1.0	41
176	Apathy in Parkinson disease. Frontiers in Biology, 2014, 9, 324-331.	0.7	7
177	Automatic detection of expressed emotion in Parkinson's Disease. , 2014, , .		18
178	Automated gait and balance parameters diagnose and correlate with severity in Parkinson disease. Journal of the Neurological Sciences, 2014, 345, 131-138.	0.3	68
179	Timed Up and Go, Cognitive, and Quality-of-Life Correlates in Parkinson's Disease. Archives of Physical Medicine and Rehabilitation, 2014, 95, 649-655.	0.5	30
180	Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hocanalysis of the RECOVER study. BMC Neurology, 2014, 14, 42.	0.8	53
181	Emergence and evolution of social self-management of Parkinson's disease: study protocol for a 3-year prospective cohort study. BMC Neurology, 2014, 14, 95.	0.8	18
182	Psychometric study of the Persian short-form eight-item Parkinson's disease questionnaire (PDQ-8) to evaluate health related quality of life (HRQoL). Health and Quality of Life Outcomes, 2014, 12, 78.	1.0	20
183	Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trial. Trials, 2014, 15, 213.	0.7	20

#	Article	IF	CITATIONS
184	Randomized cross-over trial to investigate the efficacy of a two-week physiotherapy programme with repetitive exercises of cueing to reduce the severity of freezing of gait in patients with Parkinson's disease. Clinical Rehabilitation, 2014, 28, 902-911.	1.0	49
185	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurology, The, 2014, 13, 767-776.	4.9	120
186	Parkinson's disease and REM sleep behavior disorder result in increased non-motor symptoms. Sleep Medicine, 2014, 15, 959-966.	0.8	50
187	Instrumental activities of daily living are impaired in Parkinson's disease patients with mild cognitive impairment Neuropsychology, 2014, 28, 229-237.	1.0	75
188	Validity, Reliability, and Insights from Applying the McGill Quality of Life Questionnaire to People Living with Parkinson's Disease (MQoL-PD). Journal of Palliative Care, 2015, 31, 213-220.	0.4	5
189	Assessing quality of life in Parkinson's: the nurse specialist's role. British Journal of Neuroscience Nursing, 2015, 11, 166-169.	0.1	0
190	Zonisamide improves wearingâ€off in Parkinson's disease: A randomized, doubleâ€blind study. Movement Disorders, 2015, 30, 1343-1350.	2.2	95
191	Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. Movement Disorders, 2015, 30, 1825-1830.	2.2	34
192	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. Movement Disorders Clinical Practice, 2015, 2, 127-134.	0.8	20
193	Change in Motor and Nonmotor Symptoms Severity in a "Real-Life―Cohort of Subjects with Parkinson's Disease. Neuroscience Journal, 2015, 2015, 1-5.	2.3	0
194	Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-6.	0.6	8
195	Mental Health-Related Healthcare Use Following Bilateral Deep Brain Stimulation For Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 497-504.	1.5	2
196	The Profile of Long-term Parkinson's Disease Survivors with 20 Years of Disease Duration and Beyond. Journal of Parkinson's Disease, 2015, 5, 313-319.	1.5	23
197	Transitions in Parkinson's disease in primary care: protocol of a longitudinal mixed methods study. BMJ Open, 2015, 5, e007171-e007171.	0.8	6
198	Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients. Journal of Parkinson's Disease, 2015, 5, 165-174.	1.5	93
199	Clinical phenotype of drug-naÃ⁻ve Parkinson's disease based on nonmotor symptoms. Archives of Gerontology and Geriatrics, 2015, 61, 517-522.	1.4	4
200	Preoperative brain metabolism and quality of life after subthalamic nucleus stimulation in Parkinson's disease. Journal of Neurology, 2015, 262, 881-889.	1.8	5
201	Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study. Quality of Life Research, 2015, 24, 1899-1910.	1.5	2

#	Article	IF	CITATIONS
202	Evaluating the psychometric properties of an e-based version of the 39-item Parkinson's Disease Questionnaire. Health and Quality of Life Outcomes, 2015, 13, 5.	1.0	16
203	How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease?. Archives of Physical Medicine and Rehabilitation, 2015, 96, 1728-1732.	0.5	4
204	Tango for treatment of motor and non-motor manifestations in Parkinson's disease: A randomized control study. Complementary Therapies in Medicine, 2015, 23, 175-184.	1.3	159
205	Outcome measurement in neurodegenerative disease: attributes, applications & interpretation. Neurodegenerative Disease Management, 2015, 5, 305-316.	1.2	1
206	Contribution of a Trunk Accelerometer System to the Characterization of Gait in Patients With Mild-to-Moderate Parkinson's Disease. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1803-1808.	3.9	32
207	What Engineering Technology Could Do for Quality of Life in Parkinson's Disease: A Review of Current Needs and Opportunities. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1862-1872.	3.9	66
208	The cyclical lower extremity exercise for Parkinson's trial (CYCLE): methodology for a randomized controlled trial. BMC Neurology, 2015, 15, 63.	0.8	15
209	Dysrhythmia of timed movements in Parkinson× ³ s disease and freezing of gait. Brain Research, 2015, 1624, 222-231.	1.1	20
210	Restless legs syndrome in patients with Parkinson's disease: a comparative study on prevalence, clinical characteristics, quality of life and nutritional status. Acta Neurologica Scandinavica, 2015, 131, 211-218.	1.0	60
211	Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording. Parkinson's Disease, 2016, 2016, 1-5.	0.6	15
212	Analysis and Visualization of 3D Motion Data for UPDRS Rating of Patients with Parkinson's Disease. Sensors, 2016, 16, 930.	2.1	24
213	Resistance Training with Instability for Patients with Parkinson's Disease. Medicine and Science in Sports and Exercise, 2016, 48, 1678-1687.	0.2	67
214	Healthâ€related quality of life as a predictor of recurrent falling in Parkinson's disease: 1â€year followâ€up study. Psychogeriatrics, 2016, 16, 362-367.	0.6	7
215	A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. Journal of Clinical Pharmacology, 2016, 56, 852-861.	1.0	79
216	A Pilot Study Assessing the Effects of Pallidal Deep Brain Stimulation on Sleep Quality and Polysomnography in Parkinson's Patients. Neuromodulation, 2016, 19, 724-730.	0.4	15
217	Pilot Study of a Mindfulness-Based Group Intervention for Individuals with Parkinson's Disease and Their Caregivers. Mindfulness, 2016, 7, 361-371.	1.6	44
218	Controlled pilot study of the effects of power yoga in Parkinson's disease. Complementary Therapies in Medicine, 2016, 25, 126-131.	1.3	53
219	The impact of early morning off in Parkinson's disease on patient quality of life and caregiver burden. Journal of the Neurological Sciences, 2016, 364, 1-5.	0.3	24

#	Article	IF	CITATIONS
220	High patient satisfaction with telehealth in Parkinson disease. Neurology: Clinical Practice, 2016, 6, 241-251.	0.8	83
222	Early Clinical Predictors of Treatmentâ€Resistant and Functional Outcomes in Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 53-58.	0.8	1
223	Sex Differences in the Clinical Progression of Parkinson's Disease. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2016, 45, 749-756.	0.2	31
224	Impact of Mood and Behavioral Disorders on Quality of Life in Parkinson's disease. Journal of Parkinson's Disease, 2016, 6, 267-277.	1.5	28
225	Associations and Implications of Low Health Literacy in Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 250-256.	0.8	31
226	National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemedicine Journal and E-Health, 2016, 22, 590-598.	1.6	47
227	The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT publications: a review of the current literature. Quality of Life Research, 2016, 25, 1613-1623.	1.5	53
228	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurology, The, 2016, 15, 154-165.	4.9	219
229	Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging. Journal of the Neurological Sciences, 2016, 361, 87-91.	0.3	17
230	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). Quality of Life Research, 2016, 25, 81-88.	1.5	20
231	Sleeping difficulties and health-related quality of life in Parkinson's disease. Acta Neurologica Scandinavica, 2017, 135, 459-468.	1.0	13
232	Dual tasking in Parkinson's disease: Cognitive consequences while walking Neuropsychology, 2017, 31, 613-623.	1.0	44
233	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Movement Disorders, 2017, 32, 1056-1065.	2.2	117
234	A randomized controlled feasibility trial exploring partnered ballroom dancing for people with Parkinson's disease. Clinical Rehabilitation, 2017, 31, 1340-1350.	1.0	34
235	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 197.	4.5	146
236	Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. Journal of the Neurological Sciences, 2017, 373, 116-123.	0.3	6
237	Dancing with Parkinson's: a London hospice's experience of running a dance programme. International Journal of Palliative Nursing, 2017, 23, 498-500.	0.2	2
238	Lâ€ <scp>DOPA</scp> â€induced dyskinesias, motor fluctuations and healthâ€related quality of life: the <scp>COPARK</scp> survey. European Journal of Neurology, 2017, 24, 1532-1538.	1.7	43

#	Article	IF	CITATIONS
239	Telehealth Management of Parkinson's Disease Using Wearable Sensors: An Exploratory Study. Digital Biomarkers, 2017, 1, 43-51.	2.2	45
240	Use of a self-rating scale of the nature and severity of symptoms in Parkinson's Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity. Npj Parkinson's Disease, 2017, 3, 20.	2.5	30
241	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. Journal of Parkinson's Disease, 2017, 7, 533-543.	1.5	45
242	Evaluation of PDQ-8 and its relationship with PDQ-39 in China: a three-year longitudinal study. Health and Quality of Life Outcomes, 2017, 15, 170.	1.0	21
243	Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. Journal of Neurology, 2018, 265, 1124-1137.	1.8	52
244	Back to Analogue. , 2018, , .		26
245	Effects of transcranial pulsed electromagnetic field stimulation on quality of life in Parkinson's disease. European Journal of Neurology, 2018, 25, 963.	1.7	9
246	Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy. Acta Neurologica Scandinavica, 2018, 138, 78-84.	1.0	5
247	The laser shoes. Neurology, 2018, 90, e164-e171.	1.5	77
248	Sex disparities in access to caregiving in Parkinson disease. Neurology, 2018, 90, e48-e54.	1.5	58
249	Influence of Mild Cognitive Impairment, Depression, and Anxiety on the Quality of Life of Patients with Parkinson Disease. Dementia and Geriatric Cognitive Disorders Extra, 2018, 7, 297-308.	0.6	30
250	Goal management training ® home-based approach for mild cognitive impairment in Parkinson's disease: a multiple baseline case report. Neurocase, 2018, 24, 276-286.	0.2	3
251	The Hawthorne effect as a pre-placebo expectation in Parkinsons disease patients participating in a randomized placebo-controlled clinical study. Nordic Journal of Psychiatry, 2018, 72, 442-446.	0.7	22
252	Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurology, 2018, 18, 185.	0.8	27
253	Predictors of mobility domain of health-related quality of life after rehabilitation in Parkinson's disease: a pilot study. Archives of Physiotherapy, 2018, 8, 10.	0.7	8
254	Efficacy and safety of rasagiline in Chinese patients with early Parkinson's disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. Translational Neurodegeneration, 2018, 7, 32.	3.6	7
255	A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: Does age matter?. PLoS ONE, 2018, 13, e0203637.	1.1	59
256	Patient and Family Caregiver's Neuroticism and Conscientiousness Personality in Relation to Quality of Life of Patient With Parkinson's Disease: A Cross-Sectional Study Neuroticism and Conscientiousness Personality in Relation to QoL of Patient With PD. Frontiers in Neurology, 2018, 9,	1.1	9

#	Article	IF	CITATIONS
257	Freezing of Gait Boot Camp: feasibility, safety and preliminary efficacy of a community-based group intervention. Neurodegenerative Disease Management, 2018, 8, 307-314.	1.2	5
258	Does nutritional status affect Parkinson's Disease features and quality of life?. PLoS ONE, 2018, 13, e0205100.	1.1	32
259	Cognitive Training and Transcranial Direct Current Stimulation for Mild Cognitive Impairment in Parkinson's Disease: A Randomized Controlled Trial. Parkinson's Disease, 2018, 2018, 1-12.	0.6	42
260	Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers. Journal of Neurology, 2018, 265, 2005-2014.	1.8	26
261	Predictors of clinically meaningful change in PDQ-39 in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 56, 93-97.	1.1	10
262	The use of dietary supplements and perceived quality of life in patients with Parkinson's disease. Journal of Clinical Neuroscience, 2018, 56, 137-138.	0.8	2
263	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2018, 17, 749-759.	4.9	203
964	An 8-Week Low-Intensity Progressive Cycling Training Improves Motor Functions in Patients with		

#	Article	IF	CITATIONS
275	A randomized controlled efficacy study of the Medido medication dispenser in Parkinson's disease. BMC Geriatrics, 2019, 19, 273.	1.1	5
276	Symptom progression in advanced Parkinson's disease: Dyadic perspectives. Applied Nursing Research, 2019, 50, 151193.	1.0	9
277	Sedentary Behavior and Quality of Life in Individuals With Parkinson's Disease. Neurorehabilitation and Neural Repair, 2019, 33, 595-601.	1.4	20
278	Costâ€Effectiveness of Deep Brain Stimulation With Movement Disorders: A Systematic Review. Movement Disorders Clinical Practice, 2019, 6, 348-358.	0.8	26
279	Mild cognitive impairment in Parkinson's disease: Characterization and impact on quality of life according to subtype. Geriatrics and Gerontology International, 2019, 19, 497-502.	0.7	20
280	Associations of Motor Symptom Severity and Quality of Life to Motor Task Performance in Upper and Lower Extremities Across Task Complexity in Parkinson's Disease. Motor Control, 2019, 23, 445-460.	0.3	1
281	Cognitive Problems in Parkinson Disease: Perspectives and Priorities of Patients and Care Partners. Cognitive and Behavioral Neurology, 2019, 32, 16-24.	0.5	5
282	Impact of deep brain stimulation on people with Parkinson's disease: A mixed methods feasibility study exploring lifespace and community outcomes. Hong Kong Journal of Occupational Therapy, 2019, 32, 97-107.	0.2	2
283	Understanding physical activity in Veterans with Parkinson disease: A mixed-methods approach. Parkinsonism and Related Disorders, 2019, 61, 156-160.	1.1	8
284	Predictors of self-perceived stigma in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 60, 76-80.	1.1	29
285	A Mixed-Methods Approach to Understanding the Palliative Needs of Parkinson's Patients. Journal of Applied Gerontology, 2020, 39, 834-845.	1.0	11
286	Disentangling the Role of Working Memory in Parkinson's Disease. Frontiers in Aging Neuroscience, 2020, 12, 572037.	1.7	6
287	Effectiveness of expiratory flow acceleration in patients with Parkinson's disease and swallowing deficiency: A preliminary study. Clinical Neurology and Neurosurgery, 2020, 199, 106249.	0.6	2
288	Validation of Parkinson's Disease-Related Questionnaires in South Africa. Parkinson's Disease, 2020, 2020, 1-9.	0.6	5
289	Alexithymia Is Associated with Reduced Quality of Life and Increased Caregiver Burden in Parkinson's Disease. Brain Sciences, 2020, 10, 401.	1.1	18
290	Development and Validation of a Disease-Specific Oromandibular Dystonia Rating Scale (OMDRS). Frontiers in Neurology, 2020, 11, 583177.	1.1	16
291	Wuqinxi Exercise Improves Hand Dexterity in Patients with Parkinson's Disease. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-9.	0.5	7
292	Unmasking Parkinson's Disease: The Relationship of Grit, Exercise, and Quality of Life. Journal of Patient Experience, 2020, 7, 1732-1739.	0.4	5

ARTICLE IF CITATIONS Effectiveness of 6-Week Nordic Walking Training on Functional Performance, Gait Quality, and 293 0.8 7 Quality of Life in Parkinson's Disease. Medicina (Lithuania), 2020, 56, 356. Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment. Frontiers in 294 1.1 Neurology, 2020, 11, 731. Aberrant Advanced Cognitive and Attention-Related Brain Networks in Parkinson's Disease with 295 1.0 8 Freezing of Gait. Neural Plasticity, 2020, 2020, 1-9. Health-Related Quality of Life and Physical Function in Individuals with Parkinson's Disease after a Multidisciplinary Rehabilitation Regimen—A Prospective Cohort Feasibility Study. International Journal of Environmental Research and Public Health, 2020, 17, 7668. 1.2 Pediatric Deep Brain Stimulation for Dystonia: Current State and Ethical Considerations. Cambridge 297 0.5 13 Quarterly of Healthcare Ethics, 2020, 29, 557-573. <p>Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2899-2912. 298 1.0 What contributes to quality of life in Parkinson's disease: a re-evaluation. Journal of Neurology, 299 0.9 6 Neurosurgery and Psychiatry, 2020, 91, 563-565. Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. Journal 300 1.5 of Parkinson's Disease, 2020, 10, 1171-1184. Neurophysiological Correlates of Gait in the Human Basal Ganglia and the PPN Region in Parkinson's 301 1.0 20 Disease. Frontiers in Human Neuroscience, 2020, 14, 194. A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait. 2.2 Movement Disorders, 2020, 35, 1607-1617. PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial. 303 22 1.5 Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091129. ReadySteady intervention to promote physical activity in older adults with Parkinson's disease: Study design and methods. Contemporary Clinical Trials Communications, 2020, 17, 100513. Association of Motor and Cognitive Symptoms with Health-Related Quality of Life and Caregiver Burden in a German Cohort of Advanced Parkinson's Disease Patients. Parkinson's Disease, 2020, 2020, 305 0.6 20 1-8. Sicca Symptoms in Parkinson's Disease: Association with Other Nonmotor Symptoms and 306 Health-Related Quality of Life. Parkinson's Disease, 2020, 2020, 1-7. Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in 307 1.1 16 Parkinson's Disease. Brain Sciences, 2020, 10, 111. The cost-effectiveness of specialized nursing interventions for people with Parkinson's disease: the 308 NICE-PD study protocol for a randomized controlled clinical trial. Trials, 2020, 21, 88. The Bologna motor and non-motor prospective study on parkinsonism at onset (BoProPark): study 309 0.9 6 design and population. Neurological Sciences, 2020, 41, 2531-2537. Clinical Efficacy and Transcriptomic Analysis of Congrong Shujing Granules (è‹è"‰è^'痉颗ç²') in Patients with Parkinson's Disease and Syndrome of Shen (Kidney) Essence Deficiency. Chinese Journal of Integrative Medicine, 2020, 26, 412-419.

#	Article	IF	CITATIONS
311	Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations. Movement Disorders, 2021, 36, 415-423.	2.2	24
312	The effectiveness of peroneal nerve functional electrical simulation for the reduction of bradykinesia in Parkinson's disease: A feasibility study for a randomised control trial. Clinical Rehabilitation, 2021, 35, 546-557.	1.0	6
313	Oral Levodopa Formulation Does Not Affect Progression of Parkinson Disease. Clinical Neuropharmacology, 2021, 44, 47-52.	0.2	1
314	Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations. Journal of Neural Transmission, 2021, 128, 337-344.	1.4	6
315	One Year Trajectory of Caregiver Burden in Parkinson's Disease and Analysis of Gender-Specific Aspects. Brain Sciences, 2021, 11, 295.	1.1	19
316	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism and Related Disorders, 2021, 83, 79-85.	1.1	39
317	Non-motor symptoms related to quality of life and dependency in Parkinson patients at San Pedro de Alcántara Hospital: Differences between men and women. Revista CientÃfica De La Sociedad De EnfermerÃa Neurológica (English Ed), 2021, , .	0.0	0
318	Closed-Loop Deep Brain Stimulation to Treat Medication-Refractory Freezing of Gait in Parkinson's Disease. Frontiers in Human Neuroscience, 2021, 15, 633655.	1.0	24
319	Validation of Cognitive Rehabilitation as a Balance Rehabilitation Strategy in Patients with Parkinson's Disease: Study Protocol for a Randomized Controlled Trial. Medicina (Lithuania), 2021, 57, 314.	0.8	4
320	Preditor de qualidade de vida em indivÃduos com doença de Parkinson moderada. Revista Brasileira De Educação FÃsica E Esporte: RBEFE, 2021, 35, 15-24.	0.1	1
321	Probable REM Sleep Behavior Disorder Is a Risk Factor for Symptom Progression in Parkinson Disease. Frontiers in Neurology, 2021, 12, 651157.	1.1	8
322	A Validation Study of PROMIS Sleep Disturbance (PROMIS-SD) and Sleep Related Impairment (PROMIS-SRI) Item Banks in Individuals with Idiopathic Parkinson's Disease and Matched Controls. Journal of Parkinson's Disease, 2021, 11, 877-883.	1.5	5
323	Mindfulness based stress reduction in people with Parkinson's disease and their care partners. Complementary Therapies in Clinical Practice, 2021, 43, 101377.	0.7	5
324	Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease. Movement Disorders, 2021, 36, 1979-1983.	2.2	0
326	Relationship Satisfaction in People with Parkinson's Disease and Their Caregivers: A Cross-Sectional Observational Study. Brain Sciences, 2021, 11, 822.	1.1	11
327	Altered Spontaneous Neural Activity and Functional Connectivity in Parkinson's Disease With Subthalamic Microlesion. Frontiers in Neuroscience, 2021, 15, 699010.	1.4	9
328	Lateralization of Motor Signs Affects Symptom Progression in Parkinson Disease. Frontiers in Neurology, 2021, 12, 711045.	1.1	6
329	Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown. BMC Neurology, 2021, 21, 332.	0.8	25

#	Article	IF	CITATIONS
330	Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial. Pilot and Feasibility Studies, 2021, 7, 154.	0.5	2
331	Development of a Multidimensional Assessment Tool for the Evaluation of Holistic Quality of Life in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 361-370.	1.5	4
332	Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs. Movement Disorders, 2021, 36, 2888-2900.	2.2	37
333	Longitudinal, Interdisciplinary Home Visits Versus Usual Care for Homebound People With Advanced Parkinson Disease: Protocol for a Controlled Trial. JMIR Research Protocols, 2021, 10, e31690.	0.5	8
334	ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism and Related Disorders, 2021, 91, 139-145.	1.1	27
335	Effectiveness of robotic balance training on postural instability in patients with mild Parkinson's disease: A pilot, single blind, randomized controlled trial. Journal of Rehabilitation Medicine, 2021, 53, jrm00154.	0.8	14
336	Échelles et questionnaires. , 2015, , 113-132.		2
337	The relationship between Parkinson's disease symptoms and caregiver quality of life Rehabilitation Psychology, 2020, 65, 137-144.	0.7	12
339	Symptoms and Quality of Life in Late Stage Parkinson Syndromes: A Longitudinal Community Study of Predictive Factors. PLoS ONE, 2012, 7, e46327.	1.1	83
340	Motor, Psychiatric and Fatigue Features Associated with Nutritional Status and Its Effects on Quality of Life in Parkinson's Disease Patients. PLoS ONE, 2014, 9, e91153.	1.1	48
341	Quantitative Timed-Up-and-Go Parameters in Relation to Cognitive Parameters and Health-Related Quality of Life in Mild-to-Moderate Parkinson's Disease. PLoS ONE, 2016, 11, e0151997.	1.1	37
343	Evaluation of Reliability and Validity of PDQ-39: Questionnaire in Iranian Patients With Parkinson's Disease. Zahedan Journal of Researches in Medical Sciences, 2016, 18, .	0.1	3
344	A Design to Investigate the Feasibility and Effects of Partnered Ballroom Dancing on People With Parkinson Disease: Randomized Controlled Trial Protocol. JMIR Research Protocols, 2014, 3, e34.	0.5	12
346	Validation study of Sinhala version of the dermatology life quality index (DLQI). Ceylon Medical Journal, 2011, 56, 18.	0.1	11
347	Interventional magnetic resonance imaging-guided subthalamic nucleus deep brain stimulation for Parkinson′s disease: Patient selection. , 2016, 7, 557.		5
348	Tai Chi in Parkinson's Disease: A Preliminary Randomized, Controlled, and Rater-Blinded Study. Advances in Parkinson S Disease, 2015, 04, 9-12.	0.2	10
349	The Relationship among Caregiver Burden, Demographic Variables, and the Clinical Characteristics of Patients with Parkinson's Disease—A Systematic Review of Studies Using Various Caregiver Burden Instruments. Open Journal of Nursing, 2015, 05, 855-877.	0.2	17
350	Evaluation of Assistive Technologies from the perspective of Usability, User Experience and Accessibility. , 2021, , .		0

#	Article	IF	CITATIONS
352	Lebensqualitäund tiefe Hirnstimulation. , 2004, , 405-413.		0
355	Progressive Central Nervous System Disorders. , 2007, , 436-472.		1
356	Globus Pallidus Deep Brain Stimulation for Parkinson's Disease. , 2008, , 243-252.		1
357	Treatment: minimizing impairments, activity limitations and participation restrictions. , 2009, , 127-190.		0
358	Échelles et questionnaires d'évaluation. , 2011, , 119-139.		2
359	Rural living and health-related quality of life in Australians with Parkinson's disease. Rural and Remote Health, 0, , .	0.4	7
360	Analysis of factors that reflect the quality of life of patients with parkinson's disease at a special functioning hospital. Juntendoì,, Igaku, 1999, 45, 227-239.	0.1	0
362	THE CORRELATION OF COGNITIVE, EMOTIONAL AND AFFECTIVE DISORDERS IN PATIENTS WITH PARKINSON'S DISEASE. Nevrologicheskii Zhurnal, 2016, 21, .	5 _{0.1}	2
363	Turkish version of Parkinson Fatigue Scale: Validity and reliability study of binary scoring method. Turkish Journal of Physical Medicine and Rehabilitation, 2018, 64, 253-260.	1.1	0
365	Parkinsonism and Related Disorders. , 0, , .		0
366	Quality of life in patients with Parkinson´s disease in the Slovak Republic. Neurologie Pro Praxi, 2019, 20, 219-224.	0.0	1
367	Patient-Reported and Performance-Based Outcome Measures for Functional Mobility and Activity Limitation in Individuals with Parkinson's Disease. Anadolu Kliniği Tıp Bilimleri Dergisi, 0, , .	0.1	0
369	Parkinson's disease rating scales: a literature review. Annals of Movement Disorders, 2020, 3, 3.	0.3	8
371	Development, reliability and validity of the psychosocial adaptation scale for Parkinson's disease in Chinese population. International Journal of Clinical and Experimental Medicine, 2015, 8, 19731-8.	1.3	0
372	Analysis of Parkinson's disease based on mobile application. , 2021, , 97-119.		0
373	Criteria for identification of advanced Parkinson's disease: the results of the Italian subgroup of OBSERVE-PD observational study. BMC Neurology, 2022, 22, 41.	0.8	6
374	Neuropsychiatric Symptoms in Parkinson's Disease Patients Are Associated with Reduced Health-Related Quality of Life and Increased Caregiver Burden. Brain Sciences, 2022, 12, 89.	1.1	17
375	Dopamine depletion and subcortical dysfunction disrupt cortical synchronization and metastability affecting cognitive function in Parkinson's disease. Human Brain Mapping, 2022, 43, 1598-1610.	1.9	7

#	Article	IF	CITATIONS
376	Goal management training and psychoeducation / mindfulness for treatment of executive dysfunction in Parkinson's disease: A feasibility pilot trial. PLoS ONE, 2022, 17, e0263108.	1.1	6
377	Effect of Intensive Rehabilitation Program in Thermal Water on a Group of People with Parkinson's Disease: A Retrospective Longitudinal Study. Healthcare (Switzerland), 2022, 10, 368.	1.0	4
378	Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study. Frontiers in Pharmacology, 2022, 13, 739194.	1.6	8
380	Fatigue in de novo Parkinson's Disease: Expanding the Neuropsychiatric Triad?. Journal of Parkinson's Disease, 2022, 12, 1329-1337.	1.5	5
381	The Measurement Performance of the Parkinson's Disease Activities of Daily Living, Interference, and Dependence Instrument. Frontiers in Neurology, 2022, 13, 760174.	1.1	1
382	Measuring quality of life with the Parkinson's Disease Questionnaire-39 in people with cognitive impairment. PLoS ONE, 2022, 17, e0266140.	1.1	4
383	Efficacy of Cognitive Behavioral Therapy on Mood Disorders, Sleep, Fatigue, and Quality of Life in Parkinson's Disease: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry, 2021, 12, 793804.	1.3	11
384	A method for imputing missing questionnaire data. , 0, , 165-173.		0
391	Developments in Deep Brain Stimulators for Successful Aging Towards Smart Devices—An Overview. Frontiers in Aging, 2022, 3, .	1.2	1
393	GuitarPD: A Randomized Pilot Study on the Impact of Nontraditional Guitar Instruction on Functional Movement and Well-Being in Parkinson's Disease. Parkinson's Disease, 2022, 2022, 1-12.	0.6	2
394	Training in Varying Environmental Contexts Facilitates Transfer of Improved Gait Performance to New Contexts for Individuals With Parkinson Disease: A Randomized Controlled Trial. Archives of Physical Medicine and Rehabilitation, 2022, 103, 1917-1923.	0.5	3
395	Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis. BMC Neurology, 2022, 22, .	0.8	7
396	Rhythmic cueing, dance, resistance training, and Parkinson's disease: A systematic review and meta-analysis. Frontiers in Neurology, 0, 13, .	1.1	4
397	The effect of rehabilitation interventions on freezing of gait in people with Parkinson's disease is unclear: a systematic review and meta-analyses. Disability and Rehabilitation, 2023, 45, 3199-3218.	0.9	2
398	The Predictive Relationships between Advanced Dynamic Balance and Physical Activity/Quality of Life in Parkinson's Disease. SSRN Electronic Journal, 0, , .	0.4	0
399	Tele-yoga for the management of Parkinson disease: A safety and feasibility trial. Digital Health, 2022, 8, 205520762211193.	0.9	1
400	Burden of caregiving for cardiovascular dysautonomia in Parkinson's disease. Clinical Autonomic Research, 2022, 32, 455-461.	1.4	3
401	Comparison of the Effects of an Exergame-Based Program with Conventional Physiotherapy Protocol Based on Core Areas of the European Guideline on Postural Control, Functional Mobility, and Quality of Life in Patients with Parkinson's Disease: Randomized Clinical Trial. Games for Health Journal, 2023, 12, 228-241	1.1	2

#	Article	IF	CITATIONS
402	Impact of affective and cognitive impairments on quality of life in patients with early stages of Parkinson's disease. Russian Neurological Journal, 2022, 27, 62-68.	0.1	0
403	Traditional Chinese medicine Pingchan granule for motor symptoms and functions in Parkinson's disease: A multicenter, randomized, double-blind, placebo-controlled study. Phytomedicine, 2023, 108, 154497.	2.3	5
404	APDM gait and balance measures fail to predict symptom progression rate in Parkinson's disease. Frontiers in Neurology, 0, 13, .	1.1	0
406	The Relationship between <scp>PDQ</scp> â€8 and Costs in Parkinson's Disease—A Swedish Registerâ€Based Study. Movement Disorders Clinical Practice, 2023, 10, 231-237.	0.8	1
407	Telerehabilitation during social distancing for people with Parkinson's disease: a retrospective study. Acta Neurologica Belgica, 2023, 123, 1267-1277.	0.5	4
408	The Rossy Progressive Supranuclear Palsy Centre: creation and initial experience. Canadian Journal of Neurological Sciences, 0, , 1-28.	0.3	1
409	Toward the Definition of Patient-Reported Outcome Measurements in Hereditary Spastic Paraplegia. Neurology: Genetics, 2023, 9, .	0.9	3
410	Quality of life: Seasonal fluctuation in Parkinson's disease. Frontiers in Neurology, 0, 13, .	1.1	0
411	PDQ-8: A Simplified and Effective Tool Measuring Life Quality in Progressive Supranuclear Palsy. Journal of Parkinson's Disease, 2022, , 1-9.	1.5	0
412	A retrospective evaluation of the Brain and Body Fitness Studio service on functional capacity and quality of life in people with neurological disorders. Frontiers in Neurology, 0, 13, .	1.1	0
413	Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study. Journal of Neural Transmission, 2023, 130, 125-133.	1.4	1
414	The predictive relationships between advanced dynamic balance and physical activity/quality of life in Parkinson's disease. Human Movement Science, 2023, 89, 103076.	0.6	1
415	Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study. Npj Parkinson's Disease, 2023, 9, .	2.5	15
417	Heath management app use in Parkinson's disease and quality of life during the COVID-19 pandemic. Communications Medicine, 2023, 3, .	1.9	0
418	Age as a risk factor for orthostatic hypotension induced by the levodopa challenge test in patients with Parkinson's disease: Results from a single-center trial. Medicine (United States), 2023, 102, e33161.	0.4	2
419	Sarcopenia and dynapenia is correlated to worse quality of life perception in middle-aged and older adults with Parkinson's disease. Nutritional Neuroscience, 0, , 1-9.	1.5	1
420	Impact of non-motor fluctuations on QOL in patients with Parkinsonâ \in Ms disease. Frontiers in Neurology, 0, 14, .	1.1	0
421	Randomizing a clinical trial in neuro-degenerative disease. Contemporary Clinical Trials Communications, 2023, 33, 101140.	0.5	0

#	Article	IF	CITATIONS
431	Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CNS Drugs, 2023, 37, 941-956.	2.7	0